Outcomes in unresectable and locally advanced resected cholangiocarcinoma

References

• Leong E, Chen WW, Ng E, Van Hazel G, Mitchell A, Spry N. Outcomes from combined chemoradiotherapy in unresectable and locally advanced resected cholangiocarcinoma. J. Gastrointest. Cancer DOI: 10.1007/s12029-010-9213-5 (2010) (Epub ahead of print).
   Google Scholar
• Verslype C, Prenen H, Van Cutsem E. The role of chemotherapy in biliary tract carcinoma. HPB (Oxford)10(3), 164–167 (2008).
   PubMedGoogle Scholar
• Sagawa N, Kondo S, Morikawa T, Okushiba S, Katoh H. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg. Today35(7), 548–552 (2005).
   PubMed Web of Science ®Google Scholar
• Stein DE, Heron DE, Rosato EL, Anne PR, Topham AK. Positive microscopic margins alter outcome in lymph node-negative cholangiocarcinoma when resection is combined with adjuvant radiotherapy. Am. J. Clin. Oncol.28(1), 21–23 (2005).
   PubMedGoogle Scholar
• Itoh H, Nishijima K, Kurosaka Y et al. Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder. Dig. Dis. Sci.50(12), 2231–2242 (2005).
   PubMedGoogle Scholar
• Hughes MA, Frassica DA, Yeo CJ et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int. J. Radiat. Oncol. Biol. Phys.68(1), 178–182 (2007).
   PubMedGoogle Scholar
• Shinohara ET, Mitra N, Guo M, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int. J. Radiat. Oncol. Biol. Phys.72(5), 1495–1501 (2008).
   PubMed Web of Science ®Google Scholar
• Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J. Gastroenterol.15(34), 4240–4262 (2009).
   PubMed Web of Science ®Google Scholar
• Ishii H, Furuse J, Nagase M, Kawashima M, Ikeda H, Yoshino M. Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting. Hepatogastroenterology51(58), 954–957 (2004).
   PubMedGoogle Scholar
• Takamura A, Saito H, Kamada T et al. Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma. Int. J. Radiat. Oncol. Biol. Phys.57(5), 1357–1365 (2003).
   PubMed Web of Science ®Google Scholar
• Golfieri R, Giampalma E, Fusco F et al. Unresectable hilar cholangiocarcinoma: multimodality treatment with percutaneous and intraluminal plus external radiotherapy. J. Chemother.16(Suppl. 5), 55–57 (2004).
   PubMed Web of Science ®Google Scholar
• Kuvshinoff BW, Armstrong JG, Fong Y et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br. J. Surg.82(11), 1522–1525 (1995).
   PubMed Web of Science ®Google Scholar
• Morganti AG, Trodella L, Valentini V et al. Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int. J. Radiat. Oncol. Biol. Phys.46(4), 913–919 (2000).
   PubMed Web of Science ®Google Scholar
• Nelson JW, Ghafoori AP, Willett CG et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int. J. Radiat. Oncol. Biol. Phys.73(1), 148–153 (2009).
   PubMed Web of Science ®Google Scholar
• Kim S, Kim SW, Bang YJ et al. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int. J. Radiat. Oncol. Biol. Phys.54(2), 414–419 (2002).
   PubMedGoogle Scholar
• Ben-David MA, Griffith KA, Abu-Isa E et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int. J. Radiat. Oncol. Biol. Phys.66(3), 772–779 (2006).
   PubMedGoogle Scholar
• Gerhards MF, van Gulik TM, González González D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J. Surg.27(2), 173–179 (2003).
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med.362(14), 1273–1281 (2010).
   PubMed Web of Science ®Google Scholar
• Sharma A, Dwary AD, Mohanti BK et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J. Clin. Oncol.28(30), 4581–4586 (2010).
   PubMed Web of Science ®Google Scholar
• Sharma A, Dwary AD, Mohanti BK et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J. Clin. Oncol.28(30), 4581–4586 (2010).
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med.362(14), 1273–1281 (2010).
   PubMed Web of Science ®Google Scholar
• Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br. J. Cancer96(6), 896–902 (2007).
   PubMed Web of Science ®Google Scholar
• Gatto M, Alvaro D. New insights on cholangiocarcinoma. World J. Gastrointest. Oncol.2(3), 136–145 (2010).
   PubMedGoogle Scholar
• Friman S, Foss A, Isoniemi H et al. Liver transplantation for cholangiocarcinoma: selection is essential for acceptable results. Scand. J. Gastroenterol.46(3), 370–375 (2010).
   PubMedGoogle Scholar
• Kim JH, Yoon HK, Kim SY et al. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol. Ther.29(12), 1291–1298 (2009).
   PubMedGoogle Scholar
• Zhu AX, Meyerhardt JA, Blaszkowsky LS et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a Phase 2 study. Lancet Oncol.11(1), 48–54 (2010).
   PubMed Web of Science ®Google Scholar
• Gruenberger B, Schueller J, Heubrandtner U et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a Phase 2 study. Lancet Oncol.11(12), 1142–1148 (2010).
   PubMed Web of Science ®Google Scholar
• Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J. Clin. Oncol.28(21), 3531–3540 (2010).
   PubMed Web of Science ®Google Scholar